- Home
- MYGN vs NFE Comparison
MYGN vs NFE Comparison
Compare MYGN & NFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- NFE
- Stock Information
- Founded
- MYGN 1991
- NFE 2014
- Country
- MYGN United States
- NFE United States
- Employees
- MYGN N/A
- NFE N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NFE Oil/Gas Transmission
- Sector
- MYGN Health Care
- NFE Utilities
- Exchange
- MYGN Nasdaq
- NFE Nasdaq
- Market Cap
- MYGN 2.0B
- NFE 3.0B
- IPO Year
- MYGN 1995
- NFE 2019
- Fundamental
- Price
- MYGN $13.36
- NFE $11.96
- Analyst Decision
- MYGN Hold
- NFE Buy
- Analyst Count
- MYGN 12
- NFE 6
- Target Price
- MYGN $23.92
- NFE $22.00
- AVG Volume (30 Days)
- MYGN 942.4K
- NFE 5.6M
- Earning Date
- MYGN 11-07-2024
- NFE 11-07-2024
- Dividend Yield
- MYGN N/A
- NFE 3.34%
- EPS Growth
- MYGN N/A
- NFE N/A
- EPS
- MYGN N/A
- NFE 0.91
- Revenue
- MYGN $823,600,000.00
- NFE $2,417,879,000.00
- Revenue This Year
- MYGN $13.82
- NFE N/A
- Revenue Next Year
- MYGN $4.59
- NFE $31.47
- P/E Ratio
- MYGN N/A
- NFE $13.21
- Revenue Growth
- MYGN 12.15
- NFE 11.48
- 52 Week Low
- MYGN $12.87
- NFE $7.82
- 52 Week High
- MYGN $29.30
- NFE $39.26
- Technical
- Relative Strength Index (RSI)
- MYGN 26.22
- NFE 57.72
- Support Level
- MYGN $12.87
- NFE $11.03
- Resistance Level
- MYGN $15.44
- NFE $12.22
- Average True Range (ATR)
- MYGN 0.84
- NFE 0.80
- MACD
- MYGN -0.02
- NFE -0.12
- Stochastic Oscillator
- MYGN 12.37
- NFE 55.53
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About NFE New Fortress Energy Inc.
New Fortress Energy is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to both lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include terminals and infrastructure, or T&I, and ships.